# Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)

> **NCT03829332** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 623 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **DRUG:** Lenvatinib
- **DRUG:** Placebo for lenvatinib

## Key facts

- **NCT ID:** NCT03829332
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-13
- **Primary completion:** 2021-05-19
- **Final completion:** 2024-04-24
- **Target enrollment:** 623 (ACTUAL)
- **Last updated:** 2026-02-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829332, "Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03829332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*